These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 18771087)

  • 1. Bortezomib as a therapeutic candidate for neuroblastoma.
    Armstrong MB; Schumacher KR; Mody R; Yanik GA; Opipari AW; Castle VP
    J Exp Ther Oncol; 2008; 7(2):135-45. PubMed ID: 18771087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo.
    Michaelis M; Fichtner I; Behrens D; Haider W; Rothweiler F; Mack A; Cinatl J; Doerr HW; Cinatl J
    Int J Oncol; 2006 Feb; 28(2):439-46. PubMed ID: 16391799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib induces apoptosis in human neuroblastoma CHP126 cells.
    Luo P; Lin M; Lin M; Zhu D; Wang Z; Shen J; Yang B; He Q
    Pharmazie; 2010 Mar; 65(3):213-8. PubMed ID: 20383943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.
    Amschler K; Schön MP; Pletz N; Wallbrecht K; Erpenbeck L; Schön M
    J Invest Dermatol; 2010 Apr; 130(4):1073-86. PubMed ID: 19940859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HO-1 up-regulation: a key point in high-risk neuroblastoma resistance to bortezomib.
    Furfaro AL; Piras S; Passalacqua M; Domenicotti C; Parodi A; Fenoglio D; Pronzato MA; Marinari UM; Moretta L; Traverso N; Nitti M
    Biochim Biophys Acta; 2014 Apr; 1842(4):613-22. PubMed ID: 24380881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
    Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.
    Fernández Y; Verhaegen M; Miller TP; Rush JL; Steiner P; Opipari AW; Lowe SW; Soengas MS
    Cancer Res; 2005 Jul; 65(14):6294-304. PubMed ID: 16024631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic effects of combination treatment with bortezomib and doxorubicin in human neuroblastoma cell lines.
    Du BY; Song W; Bai L; Shen Y; Miao SY; Wang LF
    Chemotherapy; 2012; 58(1):44-51. PubMed ID: 22327308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy.
    Keshelava N; Seeger RC; Groshen S; Reynolds CP
    Cancer Res; 1998 Dec; 58(23):5396-405. PubMed ID: 9850071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimized combinations of bortezomib, camptothecin, and doxorubicin show increased efficacy and reduced toxicity in treating oral cancer.
    Ding X; Matsuo K; Xu L; Yang J; Zheng L
    Anticancer Drugs; 2015 Jun; 26(5):547-54. PubMed ID: 25734832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
    Pédeboscq S; L'Azou B; Passagne I; De Giorgi F; Ichas F; Pometan JP; Cambar J
    J Exp Ther Oncol; 2008; 7(2):99-111. PubMed ID: 18771084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
    Nencioni A; Wille L; Dal Bello G; Boy D; Cirmena G; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A
    Clin Cancer Res; 2005 Jun; 11(11):4259-65. PubMed ID: 15930365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of bortezomib in combination with cisplatin and 5‑fluorouracil on 4T1 breast cancer cells.
    Yerlikaya A; Altıkat S; Irmak R; Cavga FZ; Kocacan SA; Boyaci I
    Mol Med Rep; 2013 Jul; 8(1):277-81. PubMed ID: 23660746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.
    Pagnan G; Di Paolo D; Carosio R; Pastorino F; Marimpietri D; Brignole C; Pezzolo A; Loi M; Galietta LJ; Piccardi F; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M
    Clin Cancer Res; 2009 Feb; 15(4):1199-209. PubMed ID: 19228726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
    Takigawa N; Vaziri SA; Grabowski DR; Chikamori K; Rybicki LR; Bukowski RM; Ganapathi MK; Ganapathi R; Mekhail T
    Anticancer Res; 2006; 26(3A):1869-76. PubMed ID: 16827119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.
    Bae SH; Ryoo HM; Kim MK; Lee KH; Sin JI; Hyun MS
    Oncol Rep; 2008 Apr; 19(4):1027-32. PubMed ID: 18357392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.
    Brignole C; Marimpietri D; Pastorino F; Nico B; Di Paolo D; Cioni M; Piccardi F; Cilli M; Pezzolo A; Corrias MV; Pistoia V; Ribatti D; Pagnan G; Ponzoni M
    J Natl Cancer Inst; 2006 Aug; 98(16):1142-57. PubMed ID: 16912267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy.
    Szulkin A; Nilsonne G; Mundt F; Wasik AM; Souri P; Hjerpe A; Dobra K
    PLoS One; 2013; 8(6):e65903. PubMed ID: 23840376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma.
    Hamner JB; Dickson PV; Sims TL; Zhou J; Spence Y; Ng CY; Davidoff AM
    Surgery; 2007 Aug; 142(2):185-91. PubMed ID: 17689684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.